Incontinence and Ostomy Care Global Market estimated to be worth $24.6 billion by 2026
Incontinence is the involuntary loss of urine or stool; this is a widespread condition and varies with severity from small leaks to complete loss of control of the bladder or bowel. Globally, it affects 4-8% of the population i.e., 440 million people worldwide. The two main types of incontinence are urinary incontinence and fecal incontinence. Urinary incontinence can be further classified as stress incontinence, urge incontinence, overflow incontinence, mixed incontinence and functional incontinence. Conditions affecting the bladder and bowel have a huge effect on all areas of an individual's life, from self-esteem and wellbeing to quality of life.
Ostomy surgery is a life-saving procedure that allows bodily waste to pass through a surgically created stoma on the abdomen into a ‘pouch’ or ‘ostomy bag’ on the outside of the body. Globally, number of people living with ostomy is estimated to be 6 million and number of ostomy procedures performed is 3 million in 2019. There are three main types of ostomy surgeries, the surgery which will remove the part of bladder (urostomy), small intestine (ileostomy) or large intestine (colostomy). According to IQ4I analysis, there were xx million colostomy procedures performed in 2019. Depending on the disease or wound, an ostomy may be temporary (to allow for healing and a return to normal elimination) or permanent. The technological innovations and development of personalized products in incontinence and ostomy care always improve the options available for disease treatment and getting better results. These advancements reduce healthcare costs and also it is beneficial for both doctors and patients. Incontinence and ostomy care products like adult diapers, incontinence bags, incontinence catheters, pessaries, implants (sacral nerve stimulators, tibial nerve stimulators, slings and sphincters), ostomy bags, skin barriers, deodorants and irrigation products are essential for effective management and treatment of incontinence and ostomy.
The incontinence and ostomy care global market is expected to reach $24,577.9 million by 2026 growing at a mid single digit CAGR from 2019 to 2026. Some of the factors such as increasing population prone to aging-related medical conditions, increasing R&D spending for developing innovative and technologically advanced products, and also the development of more personalized products for greater patient comfort and care are driving the market growth. Factors like growing prevalence of medical conditions such as women health-related conditions (for e.g. childbirth, menopause), inflammatory bowel diseases (Crohn's disease and ulcerative colitis), neurological diseases (multiple sclerosis, Parkinson’s disease, etc), oncology (colorectal and prostate cancer) and others diseases, increasing in awareness & acceptance of the condition of incontinence & ostomy and development of more personalized products for greater patient comfort and care, growing economies and increasing demand for better healthcare facilities in emerging markets are further substantiating enormous growth opportunities of the market. Some of the hindrances to this market growth are environmental concerns associated with disposable products, limited reimbursement facilities, presence of low cost manufactures and alternative treatments that include pharmaceutical drugs, exercises, electroceuticals, laser surgeries and radiotherapies.
The incontinence and ostomy care global market is classified based on the product, utility type, application, end-user and geography. Based on the product type, the market is segmented as incontinence care and ostomy care. The incontinence care accounted for the largest and fastest growing product segment is expected to grow at a mid single digit CAGR from 2019 to 2026 primarily due to the growing prevalence of incontinence as a result of a rapidly increasing aging population, increasing prevalence of targeted diseases, increase in awareness and acceptance of the condition of incontinence and increasing focus on product innovations. Incontinence care market based on disease type is further segmented into urinary incontinence and fecal incontinence. Urinary incontinence is the largest and fastest growing segment and expected to grow at a mid single digit CAGR from 2019 to 2026 due to increasing demand for urinary incontinence products to manage the highly prevalent urinary incontinence. Incontinence care market based on product type is further segmented into disposables and implants. Disposables segment holds largest revenue in 2019 and is expected to grow at mid single digit CAGR from 2019 to 2026 due to technological innovations in areas of infection control, newer absorption materials and personalization of the products. The implant device segment is fastest growing segment and is projected to grow at a high single digit CAGR of from 2019 to 2026 due increasing awareness about the treatment for incontinence. In disposables segment adult diapers holds the largest revenue in 2019 and is expected to grow at mid single digit CAGR from 2019 to 2026. According to IQ4I analysis, global adult diaper consumption population is estimated to be xx million in 2019 and the number of adult diapers consumed is estimated to be xx million indicating a penetration rate of xx% with an opportunity of xx% for adult diapers product manufacturers in the market.
Incontinence and ostomy care global market is classified based on utility into security & leakage control, protection & cleansing, odor control and irrigation products. Security & Leakage control segment is the largest and fastest growing segment and expected to grow at mid single digit CAGR from 2019 to 2026 due to increasing use of security and leakage control device for management or treatment incontinence and stoma conditions and increasing technological advancement in these devices to increase their efficiency.
Incontinence and ostomy care global market is classified based on application into neurological conditions, oncology, urinogenital diseases, GI Tract diseases, women health related and others. Women health related segment holds the largest revenue in 2019 and is expected grow at mid single digit CAGR from 2019 to 2026 as women are more prone to incontinence related problems such as damage to nerve controlling urine or fecal urge during childbirth and impaired sphincter function which is a result of pelvic floor weakness which in turn may be due to pregnancy & vaginal birth, surgeries related to uterus, aging and weakness of the connective tissue. Oncology segment is the fastest growing segment at mid single digit CAGR from 2019 to 2026 due to increasing prevalence of prostate cancer, colon cancer, rectal cancer and bladder cancer.
The end-users of incontinence and ostomy care market have been segmented into hospitals home care and others that consist of clinics and research institutes. Among these end users, homecare accounted for the largest share in 2019 and is expected to grow at a mid single digit CAGR during the period 2019 to 2026 due to the availability of better and technologically advanced personalized incontinence and stoma management home care products. The hospital segment is fastest growing market and is projected to grow at a mid single digit CAGR from 2019 to 2026 due to change in trend from incontinence and stoma management option to various advanced minimally invasive treatments.
The incontinence and ostomy care global market by geography is segmented into North America, Europe, Asia-Pacific and the Rest of the world (RoW). Among these regions, European region dominated the incontinence and ostomy care global market in 2019 and it is expected to grow at a low single digit CAGR from 2019 to 2026, mainly due to increasing prevalence of targeted disease in the region, escalating geriatric population, increasing penetration and adoption of advanced products and increasing R&D spending for developing innovative and technologically advanced products.
The Asia-Pacific region is the fastest-growing region and grows at high single digit CAGR from 2019 to 2026 due to increasing aging population in these countries, the increasing prevalence of the targeted disease, increasing focus to remove social stigma associated with disease, increasing per capita expenditure on healthcare needs, growing economies of these regions and growing demand for incontinence and stoma management products.
Technological advancements are rapidly revolutionizing the incontinence and ostomy care industry with innovative and value based, patient friendly devices emerging in the market every other day. Some of the major advancements in this field include development of sensor based adult diapers and ostomy bags, wearable diaper free devices and stimulation devices, next generation antibacterial solutions, advancement in biomaterials and absorbent technologies and next generation ostomy implants. For instance, Simavita Limited developed Smartz (sensor) platform technology, is a low cost sensing technology incorporated into diapers at the time of manufacture and provides accurate, real-time data and information to parents and carers at home, in aged care facilities. Integration of sensor technology in adult diapers helps in effective management of incontinence.
To avoid some of the complications associated with ostomy bags such as psychosocial problems, unwanted noise, leakage, smell, skin problems, care, etc. According to a survey conducted by UOAA found that the majority of ostomy bag-related issues experienced by users were leakage, 49%, or leakage-related (i.e. skin irritation, moisture) and 86% of long term ostomy bag users regularly experience waste leakage during bag use and while replacing full bags. So there is increased focus on the development of next-generation ostomy implants which is a breakthrough medical device in the form of discrete stoma plug with a novel technology of value closing system which can replace the need for messy colostomy bags and thereby improve the quality of life of people with ileostomy and colostomy by enhancing the restoring freedom, continence and ability to lead a normal life. For instance, OstomyCure has developed a new revolutionary solution for ileostomy patients. The TIES System (Transcutaneous Implant Evacuation System) promises a life without skin barriers and ostomy pouches.
To gain more market share by bringing innovative and differentiated products to the market and to stay abreast in the patient-driven market with smart and superior medical devices, the incontinence and ostomy care product companies are constantly striving for the launch or approval of innovative devices. For instance, in May 2019, Domtar Corporation launched new Attends Premier (briefs, underwear and premium underpads) products in their most absorbent and highest performing product line in the Attends family, This new product line includes innovations like Dry-Lock Containment Core, SmartCool Breathability and Confidence Cuff Elastics. Implantable devices used for the treatment for incontinence are also gaining much importance in forecast period due to increasing new product development and approvals. For instance, Medtronic designed a new InterStim Micro neurostimulator and also its InterStim SureScan MRI leads. InterStim Micro is a rechargeable, implantable sacral neuromodulation (SNM) device to treat patients affected by overactive bladder, urinary urge incontinence, unobstructed urinary retention and fecal incontinence. January 2020, Medtronic plc has received CE approval an InterStim Micro Neurostimulator and InterStim SureScan MRI Leads and also in December in 2018, company received U.S. Food and Drug Administration (FDA) approval of the InterStim smart programmer for use with the InterStim system (sacral nerve stimulator system). In November 2019, Axonics Modulation Technologies has received FDA approval for an SNM sacral nerve modulation system.
Inorder to take upcoming opportunities in the market, some of the companies are developing innovative products in incontinence and ostomy care, which are currently in development stage or to be approved by regulatory authorities or yet to be launched. For instance, Affluent Medical developed ARTUS (First electronically activated artificial sphincter). Company has received authorization from the French regulatory agency on medical devices to carry out its first clinical trial in France and planning to launch the device in Europe in 2021.
Funding is needed in broader approach in many aspects of incontinence and ostomy care research. Research on incontinence and ostomy care products is vital for improvement in products. Some of the start-up companies are receiving funding for developing technologically advanced products. For instance, UroMems has created an electronic artificial urinary sphincter (eAUS), an implantable medical device that treats Stress Urinary Incontinence (SUI). In May 2020, the company secured €16 million in a Series B round, a combination of equity and debt for initiating the first phase of clinical development program. Ostoform Ltd, designed FLOWASSIST protection, a combination of advanced absorbent and non-absorbent materials that prevent acidic output from contacting the patient’s skin. In October 2018, company received €1.1m ($1.2) fund to do patient trials and regulatory approval to commercialize its stoma seal in the US and Europe and also OstomyCure AS received the Horizon 2020 EU grant of €2.5 Million ($2.8). This grant will further enable OstomyCure to bring the TIES Solution to the market more efficiently. Funding will help to brings innovative technologically advanced products in the market for effective management and treatment for disease conditions.
The incontinence and ostomy care market is consolidated with the top ten players occupying xx% of the market share and the remaining xx% of the market being occupied by other players. The top players in incontinence and ostomy care market are Essity AB (Sweden), Coloplast A/S (Denmark), Kimberly-Clark Corporation (U.S.), Unicharm Corporation (Japan), ConvaTec Group Plc (U.K.), B. Braun Melsungen AG (Germany), Medtronic, Plc (Ireland), Ontex (Belgium), Paul Hartmann AG (Germany), Procter & Gamble Company (U.S.), Hollister Incorporated (U.S.), Salts Healthcare (U.K.), First Quality Enterprises, Inc. (U.S.), Abena A/S (Denmark), Becton, Dickinson and Company (U.S.), Medline Industries, Inc., (U.S.) and Domtar Corporation (U.S.).